GenMont Biotech Incorporation
Taiwan Stock Exchange 3164.TW
GenMont Biotech Incorporation Operating Income for the year ending December 31, 2023: USD 227.63 K
GenMont Biotech Incorporation Operating Income is USD 227.63 K for the year ending December 31, 2023, a -89.30% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.
-
GenMont Biotech Incorporation Operating Income for the year ending December 31, 2022 was USD 2.13 M, a -58.89% change year over year.
-
GenMont Biotech Incorporation Operating Income for the year ending December 31, 2021 was USD 5.18 M, a 89.09% change year over year.
-
GenMont Biotech Incorporation Operating Income for the year ending December 31, 2020 was USD 2.74 M, a 8.51% change year over year.
-
GenMont Biotech Incorporation Operating Income for the year ending December 31, 2019 was USD 2.52 M, a -37.19% change year over year.
Key data
| Date | Operating Income | EBIT | EBITDA | Net Income |
|---|
Market news
Loading...
Taiwan Stock Exchange: 3164.TW
| CEO | Yu Chin Chen |
| IPO Date | Sept. 19, 2008 |
| Location | Taiwan |
| Headquarters | No.8, Nanke 7th Road |
| Employees | 147 |
| Sector | Health Care |
| Industries | |
Description
GenMont Biotech Incorporation engages in the research, development, production, and sale of functional probiotic products in Taiwan. The company also offers probiotics with special functions; and original formula design and manufacturing, and equipment manufacturing services on health care food, as well as cooperates in the research, production, and clinical trial of various products. GenMont Biotech Incorporation was founded in 2000 and is headquartered in Tainan City, Taiwan.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email